Summary
Citations
Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024 Jan 1;119(1):30-54.[Abstract][Full Text]
Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023 Mar 1;77(3):1036-65.[Full Text]
Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol. 2022 Feb 1;117(2):225-52.[Abstract][Full Text]
Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.[Abstract][Full Text]
American College of Radiology. ACR appropriateness criteria: jaundice. 2018 [internet publication].[Full Text]
1. King D, Armstrong MJ. Overview of Gilbert's syndrome. Drug Ther Bull. 2019 Feb;57(2):27-31.[Abstract]
2. Centers for Disease Control and Prevention. Viral hepatitis: clinical overview of viral hepatitis. Jan 2025 [internet publication].[Full Text]
3. Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E, et al. Pharmacological interventions for acute hepatitis B infection. Cochrane Database Syst Rev. 2017 Mar 21;(3):CD011645.[Abstract][Full Text]
4. World Health Organization. Hepatitis B. Apr 2024 [internet publication].[Full Text]
5. Li J, Dong XQ, Cao LH, et al. Factors associated with persistent positive in HBV DNA level in patients with chronic hepatitis B receiving entecavir treatment. Front Cell Infect Microbiol. 2023;13:1151899.[Abstract][Full Text]
6. Grossi G, Viganò M, Loglio A, et al. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int. 2017 Jan;37 Suppl 1:45-51.[Abstract][Full Text]
7. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Mar 2024 [internet publication].[Full Text]
8. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001 Oct;34(4 pt 1):809-16.[Abstract]
9. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008 Aug;48(2):418-31.[Abstract]
10. World Health Organization. Hepatitis C. Apr 2024 [internet publication].[Full Text]
11. Martinello M, Solomon SS, Terrault NA, et al. Hepatitis C. Lancet. 2023 Sep 23;402(10407):1085-96.[Abstract]
12. US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, et al. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020 Mar 10;323(10):970-5.[Abstract][Full Text]
13. Centers for Disease Control and Prevention. Hepatitis D: hepatitis D basics. Apr 2024 [internet publication].[Full Text]
14. European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis delta virus. J Hepatol. 2023 Aug;79(2):433-60.[Abstract][Full Text]
15. Songtanin B, Molehin AJ, Brittan K, et al. Hepatitis E virus infections: epidemiology, genetic diversity, and clinical considerations. Viruses. 2023 Jun 17;15(6):1389.[Abstract][Full Text]
16. Wu C, Wu X, Xia J. Hepatitis E virus infection during pregnancy. Virol J. 2020 Jun 10;17(1):73.[Abstract][Full Text]
17. Jilani N, Das BC, Husain SA, et al. Hepatitis E virus infection and fulminant hepatic failure during pregnancy. J Gastroenterol Hepatol. 2007 May;22(5):676-82.[Abstract]
18. Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol. 2010 Dec;8(12):1002-12.[Abstract][Full Text]
19. Whitty CJ, Chiodini PL, Lalloo DG. Investigation and treatment of imported malaria in non-endemic countries. BMJ. 2013 May 21;346:f2900.[Abstract]
20. Wuerz T, Kane JB, Boggild AK, et al. A review of amoebic liver abscess for clinicians in a nonendemic setting. Can J Gastroenterol. 2012 Oct;26(10):729-33.[Abstract][Full Text]
21. Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015 Sep 17;9(9):e0003898.[Abstract][Full Text]
22. Centers for Disease Control and Prevention. Leptospirosis: clinical overview of Leptospirosis. Apr 2025 [internet publication].[Full Text]
23. De Brito T, Aiello VD, da Silva LF, et al. Human hemorrhagic pulmonary leptospirosis: pathological findings and pathophysiological correlations. PLoS One. 2013 Aug 12;8(8):e71743.[Abstract][Full Text]
24. Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024 Jan 1;119(1):30-54.[Abstract][Full Text]
25. Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA. 2021 Jul 13;326(2):165-76.[Abstract]
26. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018 Aug 16;4(1):16.[Abstract]
27. Lee WM. Drug-induced acute liver failure. Clin Liver Dis. 2013 Nov;17(4):575-86;viii.[Abstract][Full Text]
28. Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017 Jun;66(6):1154-64.[Abstract][Full Text]
29. Hoofnagle JH, Björnsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med. 2019 Jul 18;381(3):264-73.[Abstract]
30. Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023 Mar 1;77(3):1036-65.[Full Text]
31. Chalasani NP, Maddur H, Russo MW, et al. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021 May 1;116(5):878-98.[Abstract][Full Text]
32. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013 Jun;144(7):1419-25, 1425.e1-3; quiz e19-20.[Abstract][Full Text]
33. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002 Aug;36(2):451-5.[Abstract][Full Text]
34. European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222-61.[Abstract][Full Text]
35. Tujios SR, Lee WM. Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Liver Int. 2018 Jan;38(1):6-14.[Abstract][Full Text]
36. Björnsson ES. Drug-induced liver injury due to antibiotics. Scand J Gastroenterol. 2017 Jun-Jul;52(6-7):617-23.[Abstract]
37. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014 Oct;60(4):1399-408.[Abstract][Full Text]
38. Nichols SD, Albert S, Shirley L, et al. Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management. J Gastrointest Surg. 2014 Dec;18(12):2186-91.[Abstract][Full Text]
39. Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022 Oct 15;400(10360):1345-62.[Abstract]
40. Birrer MJ, Young RC. Differential diagnosis of jaundice in lymphoma patients. Semin Liver Dis. 1987 Aug;7(3):269-77.[Abstract]
41. Lleo A, Wang GQ, Gershwin ME, et al. Primary biliary cholangitis. Lancet. 2020 Dec 12;396(10266):1915-26.[Abstract]
42. Lv T, Chen S, Li M, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2021 Jun;36(6):1423-34.[Abstract]
43. Gazda J, Drazilova S, Janicko M, et al. The epidemiology of primary biliary cholangitis in European countries: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2021;2021:9151525.[Abstract][Full Text]
44. Mehta TI, Weissman S, Fung BM, et al. Global incidence, prevalence and features of primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Int. 2021 Oct;41(10):2418-26.[Abstract]
45. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines on sclerosing cholangitis. J Hepatol. 2022 Sep;77(3):761-806.[Abstract][Full Text]
46. Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet. 2018 Jun 23;391(10139):2547-59.[Abstract]
47. Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019 Aug;68(8):1356-78.[Abstract][Full Text]
48. Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2022 Dec 7.[Abstract][Full Text]
49. Patil M, Sheth KA, Krishnamurthy AC, et al. A review and current perspective on Wilson disease. J Clin Exp Hepatol. 2013 Dec;3(4):321-36.[Abstract][Full Text]
50. Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.[Abstract][Full Text]
51. Björnsson E, Chari ST, Smyrk TC, et al. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007 Jun;45(6):1547-54.[Abstract][Full Text]
52. Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of pancreatic cancer in primary care: a systematic review. Pancreas. 2016 Jul;45(6):814-8.[Abstract]
53. National Cancer Institute; surveillance, epidemiology and end results program. Cancer stat facts: pancreatic cancer. 2025 [internet publication].[Full Text]
54. Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702.[Abstract][Full Text]
55. Gulamhusein AF, Eaton JE, Tabibian JH, et al. Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol. 2016 May;111(5):705-11.[Abstract][Full Text]
56. Huai JP, Ding J, Ye XH, et al. Inflammatory bowel disease and risk of cholangiocarcinoma: evidence from a meta-analysis of population-based studies. Asian Pac J Cancer Prev. 2014;15(8):3477-82.[Abstract]
57. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005 Mar;128(3):620-6.[Abstract][Full Text]
58. Kubo S, Takemura S, Tanaka S, et al. Occupational cholangiocarcinoma caused by exposure to 1,2-dichloropropane and/or dichloromethane. Ann Gastroenterol Surg. 2017 Nov 17;2(2):99-105.[Abstract][Full Text]
59. Kumagai S, Sobue T, Makiuchi T, et al. Relationship between cumulative exposure to 1,2-dichloropropane and incidence risk of cholangiocarcinoma among offset printing workers. Occup Environ Med. 2016 Aug;73(8):545-52.[Abstract]
60. Duraiswamy S, Sheffield JS, Mcintire D, et al. Updated etiology and significance of elevated bilirubin during pregnancy: changes parallel shift in demographics and vaccination status. Dig Dis Sci. 2017 Feb;62(2):517-25.[Abstract]
61. Mackle IJ, Swann DG, Cook B. One year outcome of intensive care patients with decompensated alcoholic liver disease. Br J Anaesth. 2006 Oct;97(4):496-8.[Abstract][Full Text]
62. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006 Jan;44(1):217-31.[Full Text]
63. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-60.[Abstract][Full Text]
64. Rumsey S, Winders J, MacCormick AD. Diagnostic accuracy of Charcot's triad: a systematic review. ANZ J Surg. 2017 Apr;87(4):232-8.[Abstract]
65. National Institute for Health and Care Excellence. Suspected sepsis: recognition, diagnosis and early management. Mar 2024 [internet publication].[Full Text]
66. Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019 Sep 7;394(10201):869-81.[Abstract]
67. European Association for the Study of the Liver. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017 May;66(5):1047-81.[Abstract][Full Text]
68. Nanchal R, Subramanian R, Karvellas CJ, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. Crit Care Med. 2020 Mar;48(3):e173-91.[Abstract][Full Text]
69. Nanchal R, Subramanian R, Alhazzani W, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: neurology, peri-transplant medicine, infectious disease, and gastroenterology considerations. Crit Care Med. 2023 May 1;51(5):657-76.[Abstract][Full Text]
70. Shingina A, Mukhtar N, Wakim-Fleming J, et al. Acute liver failure guidelines. Am J Gastroenterol. 2023 Jul 1;118(7):1128-53.[Abstract][Full Text]
71. Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014 Mar;59(3):1144-65.[Abstract][Full Text]
72. Hernaez R, Solà E, Moreau R, et al. Acute-on-chronic liver failure: an update. Gut. 2017 Mar;66(3):541-53.[Abstract][Full Text]
73. Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol. 2022 Feb 1;117(2):225-52.[Abstract][Full Text]
74. Sarin SK, Choudhury A. Management of acute-on-chronic liver failure: an algorithmic approach. Hepatol Int. 2018 Sep;12(5):402-16.[Abstract]
75. Aggarwal A, Biswas S, Arora U, et al. Definitions, etiologies, and outcomes of acute on chronic liver failure: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024 Nov;22(11):2199-210.e25.[Abstract][Full Text]
76. Fernández J, Acevedo J, Wiest R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018 Oct;67(10):1870-80.[Abstract]
77. Bajaj JS, Kamath PS, Reddy KR. The evolving challenge of infections in cirrhosis. N Engl J Med. 2021 Jun 17;384(24):2317-30.[Abstract]
78. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013 Jun;144(7):1426-37;e1-9.[Abstract][Full Text]
79. Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014 Nov;61(5):1038-47.[Abstract]
80. European Association for the Study of the Liver. EASL clinical practice guidelines on acute-on-chronic liver failure. J Hepatol. 2023 Aug;79(2):461-91.[Abstract][Full Text]
81. National Institute for Health and Care Excellence. Cirrhosis in over 16s: assessment and management. Sep 2023 [interner publication].[Full Text]
82. British Society of Gastroenterology, British Society for the Study of the Liver. Decompensated cirrhosis care bundle - first 24 hours. 2014 [internet publication].[Full Text]
83. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.[Abstract][Full Text]
84. Bataller R, Arab JP, Shah VH. Alcohol-associated hepatitis. N Engl J Med. 2022 Dec 29;387(26):2436-48.
85. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005 Feb;41(2):353-8.[Abstract]
86. Van Melkebeke L, Korf H, Tsochatzis EA, et al. Treatment of severe alcoholic hepatitis: a systematic review. Curr Opin Pharmacol. 2021 Oct;60:91-101.[Abstract]
87. Pavlov CS, Varganova DL, Casazza G, et al. Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database Syst Rev. 2019 Apr 9;(4):CD001511.[Abstract][Full Text]
88. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54.[Abstract][Full Text]
89. Garcia-Saenz-de-Sicilia M, Duvoor C, Altamirano J. A day-4 Lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis. Am J Gastroenterol. 2017 Feb;112(2):306-15.[Abstract]
90. Thursz MR, Richardson P, Allison M, et al; STOPAH trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015 Apr 23;372(17):1619-28.[Abstract][Full Text]
91. van Lingen R, Warshow U, Dalton HR, et al. Jaundice as a presentation of heart failure. J R Soc Med. 2005 Aug;98(8):357-9.[Abstract][Full Text]
92. Win TZ, Han SM, Edwards T, et al. Antibiotics for treatment of leptospirosis. Cochrane Database Syst Rev. 2024 Mar 14;3(3):CD014960.[Abstract][Full Text]
93. Bassari R, Koea JB. Jaundice associated pruritis: a review of pathophysiology and treatment. World J Gastroenterol. 2015 Feb 7;21(5):1404-13.[Abstract][Full Text]
94. Stillman AE. Jaundice. In: Walker HK, Hall WD, Hurst JW, eds. Clinical methods: the history, physical, and laboratory examinations. 3rd ed. Boston: Butterworths; 1990.[Full Text]
95. Centers for Disease Control and Prevention. Hepatitis C: clinical overview of hepatitis C. Jan 2025 [internet publication].[Full Text]
96. Berner MM, Kriston L, Bentele M, et al. The alcohol use disorders identification test for detecting at-risk drinking: a systematic review and meta-analysis. J Stud Alcohol Drugs. 2007 May;68(3):461-73.[Abstract]
97. Crawford EF, Fulton JJ, Swinkels CM, et al. Diagnostic efficiency of the AUDIT-C in US veterans with military service since September 11, 2001. Drug Alcohol Depend. 2013 Sep 1;132(1-2):101-6.[Abstract]
98. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for hepatitis B virus infection in adolescents and adults: US preventive services task force recommendation statement. JAMA. 2020 Dec 15;324(23):2415-22.[Abstract][Full Text]
99. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35.[Abstract][Full Text]
100. Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. Dig Dis Sci. 1979 Nov;24(11):835-8.[Abstract]
101. Mitchell MC, Friedman LS, McClain CJ. Medical management of severe alcoholic hepatitis: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017 Jan;15(1):5-12.[Abstract][Full Text]
102. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005 Aug;54(8):1174-9.[Abstract][Full Text]
103. Arnold J, Avila E, Idalsoaga F, et al. Advances in the diagnosis and management of hepatorenal syndrome: insights into HRS-AKI and liver transplantation. eGastroenterology. 2023 Sep;1(2):e100009.[Abstract][Full Text]
104. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48.[Abstract][Full Text]
105. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.[Abstract][Full Text]
106. Bernardi M, Caraceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81.[Abstract][Full Text]
107. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021 Jan;70(1):9-29.[Abstract][Full Text]
108. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol. 2000 Jan;32(1):142-53.[Abstract]
109. American College of Radiology. ACR appropriateness criteria: jaundice. 2018 [internet publication].[Full Text]
110. Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Feb;34(2):127-40.[Abstract][Full Text]
111. Rushbrook SM, Kendall TJ, Zen Y, et al. British society of gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2023 Dec 7;73(1):16-46.[Abstract][Full Text]
112. Kolodziejczyk E, Jurkiewicz E, Pertkiewicz J, et al. MRCP versus ERCP in the evaluation of chronic pancreatitis in children: which is the better choice? Pancreas. 2016 Sep;45(8):1115-9.[Abstract]
113. Scaffidi MG, Luigiano C, Consolo P, et al. Magnetic resonance cholangio-pancreatography versus endoscopic retrograde cholangio-pancreatography in the diagnosis of common bile duct stones: a prospective comparative study. Minerva Med. 2009 Oct;100(5):341-8.[Abstract]
114. National Institute for Health and Care Excellence. Pancreatic cancer in adults: diagnosis and management. Feb 2018 [internet publication].[Full Text]
115. Conroy T, Pfeiffer P, Vilgrain V, et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Nov;34(11):987-1002.[Full Text]
116. Elmunzer BJ, Maranki JL, Gómez V, et al. ACG clinical guideline: diagnosis and management of biliary strictures. Am J Gastroenterol. 2023 Mar 1;118(3):405-26.[Abstract][Full Text]
117. Manes G, Paspatis G, Aabakken L, et al. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2019 May;51(5):472-91.[Abstract][Full Text]
118. Whitfield JB, Masson S, Liangpunsakul S, et al. Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol. 2018 Feb;66:1-7.[Abstract][Full Text]
119. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985 Apr;151(4):599-603.[Abstract]
120. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. May 2025 [internet publication].[Full Text]
121. O'Grady JG, Alexander GJ, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989 Aug;97(2):439-45.[Abstract][Full Text]
122. Korman JD, Volenberg I, Balko J, et al. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology. 2008 Oct;48(4):1167-74.[Abstract]
123. Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002 Aug;51(2):265-9.[Abstract][Full Text]